Zenas Biopharma announced mid‑stage MoonStone data showing its bifunctional monoclonal antibody obexelimab produced a 95% reduction in new gadolinium‑enhancing brain lesions in relapsing multiple sclerosis patients at 12 weeks. The company reported the primary endpoint was met with a safety profile consistent with prior studies and plans further readouts, including 24‑week data that will include secondary and exploratory endpoints. The result validates obexelimab’s mechanism targeting B‑cell pathways and could accelerate development plans across autoimmune indications; Zenas will use the data to inform pivotal strategy and upcoming registrational discussions.